Melatonin is more effective than olanzapine in improving sleep quality in cancer patients with insomnia, with a superior adverse effect profile.
In a prospective, double-blind, randomized trial of 60 advanced cancer patients with insomnia, both oral melatonin (3 mg/day) and oral olanzapine (5 mg/day) significantly improved sleep parameters over four weeks (p < 0.001). Melatonin showed statistically significant superiority over olanzapine in PSQI scores at week four and overall AIS scores across all time points, and had a more favorable adverse effect profile (olanzapine was associated with somnolence, akathisia, and weight gain).
This article is automatically generated from the structured evidence profile behind the claim above. Scores reflect the quality and quantity of available research, not clinical advice.
Melatonin is more effective than olanzapine in improving sleep quality in cancer patients with insomnia, with a superior adverse effect profile. The current body of evidence comprises 1 study, including 1 randomized controlled trial. EvidenceHub rates the overall confidence at 44/100 (low).
The Claim
Melatonin is more effective than olanzapine in improving sleep quality in cancer patients with insomnia, with a superior adverse effect profile.
This conclusion is most relevant to: 60 advanced cancer patients with insomnia.
What the Research Shows
The conclusion draws on 1 linked study. Highlights from the cited literature:
- ▸Efficacy of Oral Melatonin Versus Oral Olanzapine in Improving Sleep in Cancer Patients with Insomnia: Prospective Comparative Study. (Journal of pain & palliative care pharmacotherapy, 2026) —
How It Works
The proposed biological pathway:
- ▸Melatonin regulates circadian rhythms and sleep-wake cycle via MT1 and MT2 receptors.
- ▸Olanzapine blocks histamine H1, dopamine D2, and serotonin 5-HT2A receptors, causing sedation.
- ▸Melatonin's action is more specific to sleep regulation, potentially leading to better sleep quality with fewer side effects.
- ▸Result: Melatonin improved PSQI and AIS scores more than olanzapine, with fewer adverse effects.
Who Might Benefit
Evidence fit by population:
- ▸60 advanced cancer patients with insomnia
Recommended Dose
Melatonin 3 mg/day; olanzapine 5 mg/day
Limitations & Caveats
Important context when interpreting this evidence:
- ▸Small sample size (n=60) limits generalizability.
- ▸No placebo control group, so absolute efficacy cannot be established.
- ▸Objective sleep measures (e.g., polysomnography) were not used; relied on subjective questionnaires.
- ▸Short duration (4 weeks) may not reflect long-term effects.
Frequently Asked Questions
Is melatonin better than olanzapine for sleep in cancer patients?▼
Yes, in this study, melatonin showed statistically significant superiority over olanzapine in improving PSQI scores at week 4 and overall AIS scores, with a better side effect profile.
What dose of melatonin was used in this study?▼
The dose was 3 mg per day, taken orally for four weeks.
What are the common side effects of olanzapine in this context?▼
Olanzapine was associated with somnolence, akathisia, and weight gain, whereas melatonin had a more favorable adverse effect profile.
How was sleep quality measured in this trial?▼
Sleep quality was assessed using the Pittsburgh Sleep Quality Index (PSQI) and Athens Insomnia Scale (AIS) at baseline, 2 weeks, and 4 weeks.
References
- 1.Pingoliya SK, Garg DK, Abdulla S, Bhaskar A. “Efficacy of Oral Melatonin Versus Oral Olanzapine in Improving Sleep in Cancer Patients with Insomnia: Prospective Comparative Study..” Journal of pain & palliative care pharmacotherapy, 2026. PMID: 42536921 DOI: 10.1080/15360288.2026.2707225